Alto Neuroscience Inc. (ANRO)
NYSE: ANRO · Pharmaceutical Preparations · Mountain View, CA · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 16, 2026 | Mar 20, 2025 | Mar 21, 2024 |
| Research and development | 45,619 | 46,996 | 30,291 |
| General and administrative | 20,745 | 21,614 | 7,518 |
| Total operating expenses | 66,364 | 68,610 | 37,809 |
| Operating income | -66,364 | -68,610 | -37,809 |
| Interest expense | 2,469 | 1,375 | 1,370 |
| Interest and investment income | 6,603 | 8,851 | 2,349 |
| Total non-operating income (expense) | 3,126 | 7,179 | 1,504 |
| Income tax expense | 0 | 0 | 0 |
| Net income | -63,238 | -61,431 | -36,305 |
| Earnings per share, basic | -2.19 | -2.50 | -9.73 |
| Earnings per share, diluted | -2.19 | -2.50 | -9.73 |
| Weighted average shares, basic | 28,852 | 24,602 | 3,731 |
| Weighted average shares, diluted | 28,852 | 24,602 | 3,731 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding